Similar to our study, treatment of male and female C57BL/6 mice with another TLR7 agonist, resiquimod, over a similar time-frame promoted splenomegaly, no significant rise in dsDNA autoantibodies but a significant increase in ANA (Wirth et al., 2020). This evidence concerns the gene TLR7 and Splenomegaly.